Clonal Hematopoiesis of Indeterminate Potential
9
5
5
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
11%
1 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (9)
Pre-malignant States to Hematologic Malignancies in Firefighters
Metabolic Profiling of Hematopoietic Stem Cells in Clonal Hematopoiesis (CHIP)
Clonal Hematopoiesis of Immunological Significance
CHIP/CCUS Natural History Protocol
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
Effect of Colchicine on Progression of Coronary Atherosclerosis in Patients With TET2-CHIP Variant
CHIP and Residual Cardiovascular Event Tendency After Smoking Cessation
Clonal Hematopoiesis and NETs Formation in Venous Thrombosis (CLODETTE)
Clonal Hematopoiesis in Giant Cell Arteritis